Avastin

Avastin, Avastin what? known as that Avastin is a drug used for patients with breast cancer. This drug was developed by Genentech in South San Francisco area. But on Wednesday, oncologists do not use drug. Because the drug is feared can not work properly and make cause bleeding that can make the patient lose his life.

This medicine will be sent to the FDA commissioner Margaret Hamburg, who will check the drug and will make a final decision at an undetermined time. But the drugs used for patients with breast cancer will still be sold in the market, since it was approved as a drug for four types of tumor disease. While the decision to be decided over two days, the patient continued to press to using the drug but FDA scientists maintain that the drug is very dangerous. After considering all aspects of the present, experts have concluded that the drug did not have great benefits but it can take a huge risk.

 

Some advisers think the same, that the drugs consumed by mothers suffering from breast cancer did not bring good benefits. Decisions made by the experts did not interfere with the use of Avastin against other diseases, like lung cancer, metastatic colorectal cancer, metastatic renal cell carcinoma, and glioblastoma brain tumors.

This decision is a blow for Genentech, which is the manufacturer of Avastin, also known as bevacizumab. In 2008 the company has conducted research that produced that Avastin can slow the progression of breast cancer with an average of 5.5 months. But from time to time there is a study conducted by the FDA have shown that these drugs can not help patients live longer to enjoy a good quality of life with diseases that nested in the body. These drugs carry side effects, sometimes fatal, and eventually heart attack.

 

After several statements of this drug, the patient representative Natalie Compagni Portis said that "we urgently need drugs to survive, research that you did not bring good results.

"Heraleen Broome is one of breast cancer patients, said that Avastin is my savior after chemotherapy failed eight years ago, and the drug should remain on the market although the greatest risk may occur at any time.